Product
SB-913
2 clinical trials
3 indications
Indication
MPS IIIndication
Hemophilia BIndication
Mucopolysaccharidosis Type IClinical trial
A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis II (MPS II)Status: Terminated, Estimated PCD: 2021-05-07
Clinical trial
Long-Term Follow-up of Subjects Who Were Treated With SB-318, SB-913, or SB-FIX, for Targeted Genome Editing Into the Albumin Gene in the LiverStatus: Active (not recruiting), Estimated PCD: 2030-01-01